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ABSTRACT 
Background: Myocardial infarction with normal coronary arteries (MINCA) is a common condition that 
mostly affects middle-aged women. The pathogenesis is complex and includes various mechanisms that need 
to be explored for appropriate diagnosis and treatment. Patients with MINCA often complain about low 
energy and appear to be distressed. Previous studies in MINCA with control groups were lacking when the 
Stockholm myocardial infarction and normal coronaries (SMINC) study started. 
Aims: To describe cardiac magnetic resonance (CMR) imaging findings, background characteristics, 
atherosclerosis markers and quality-of-life (QoL) in patients with MINCA. The intention is to better 
understand and improve the management of this group of patients. 
Specific aims, methods and results: 
Study I: The aim was to report the true prevalence of myocarditis and MINCA with or without myocardial 
infarction by using CMR. We investigated 152 patients 35-70 years and found that 67% had a normal CMR, 
19% had signs of myocardial necrosis and 7% had signs of myocarditis. Twenty-two percent of all MINCA 
with a normal CMR fulfilled the Mayo clinical diagnostic criteria for TS. The CMR was performed a median 
of 12 days (6-28 days) after the acute event. 
Study 2: The aim was to describe the risk factors by analysing the case record form (CRF) and different 
investigations performed during the 3 months follow up after the acute event in patients with MINCA and 
compare those with two control groups. We analysed blood samples, reactive hyperaemia index (RHI) and 
intima-media thickness (IMT) by using EndoPAT® (Itamar Medical Ltd) and ultrasound of the carotids. The 
results showed that MINCA was associated with similar risk factors as in coronary heart disease (CHD) 
patients except for a more favourable lipid profile. The atherosclerotic burden in MINCA, measured as RHI 
and IMT, were within the normal range and similar to both healthy and CHD controls. Psychiatric disorders 
were more common in patients with MINCA and TS than those without TS and more than half of all MINCA 
patients recalled physical and emotional stress before admission.  
Study 3: The aim was to describe the physical capacity and QoL 6 weeks to 3 months after the acute event in 
MINCA compared to both control groups using an exercise bicycle stress test and Short Form (SF)-36. The 
findings showed that patients with MINCA had a lower exercise capacity and QoL compared with healthy 
controls. Compared with CHD controls the results showed better exercise capacity in MINCA but lower 
mental and vitality scores in the mental component of SF-36, otherwise the dimensions were similar.  
Study 4: The aim was to evaluate mental health in MINCA patients and compare them with two control 
groups by using two different surveys 3 months after the acute event; the Beck Depression Inventory (BDI) 
and the Hospital Anxiety and Depression scale (HADS). Our findings showed that anxiety and depression 
were common with prevalence rates similar to patients with CHD. Anxiety was more common in patients 
with MINCA and TS than those without TS. 
Conclusions: CMR imaging is an important tool that can help us to identify the different underlying 
diagnoses in MINCA and enable a more adequate treatment. Patients with MINCA do not have signs of early 
or generalized atherosclerosis and they share a number of cardiovascular risk factors with patients who have 
CHD, including high prevalence of anxiety and depression. There is also a decline in QoL similar to that of 
CHD patients and in some perspectives even worse in the domain of mental health. Altogether these findings 
show a high vulnerability to mental stress in patients with MINCA. The lack of clarity regarding diagnosis 
and treatment can also increase the stress and therefore highlight the need for a change in the management 
care of patients with MINCA, not only in the hospital but also after being discharged. Performing CMR early 
(2 weeks from presentation) and follow-up care in in a similar way as in patients with CHD will probably 
decrease the mental stress and improve QoL. 
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INTRODUCTION 
 
During the last century several medical developments have been introduced in 
our cardiac clinics with the aim of improving health and reducing mortality. 
The first portable ECG machine was introduced in the beginning of last 
century and the first coronary care unit was established in Scotland 1964 1. 
When the era of coronary angiography and percutaneous coronary 
interventions started 50 years ago, non-obstructed coronary arteries in patients 
with acute myocardial infarction (AMI) was considered as a benign condition 
and the focus was to prevent and treat patients with obstructed coronary 
arteries. The cause of “normal” coronary arteries was thought to be 
spontaneous reperfusion, missed coronary artery lesion, coronary spasm or 
secondary due to other reasons such as anaemia 2. In past decades myocardial 
infarction with non-obstructive coronary arteries (MINOCA) has been 
recognized due to sensitive troponin assays and increased number of coronary 
angiograms performed after AMI 3. Compared to patients with obstructed 
coronary arteries, patients with MINOCA are younger and women are more 
affected 4. In general the prognosis is relatively good compared to patients 
with obstructed coronary arteries but recent long-term mortality data after 
coronary angiogram showed that one-third of deaths occurred in women 
without obstructive coronary arteries 5. There are large gaps of knowledge 
regarding etiology, diagnosis and treatments in MINOCA syndrome. Patients 
also appear to have difficulties in coping with their new situation and many of 
them are reporting anxiety and lack of physical and mental energy for a 
prolonged time after leaving the hospital. Some possible reasons for this could 
be medical uncertainty regarding diagnosis or lack of follow-up care similar to 
patients with obstructed coronary arteries 6,7.  
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BACKGROUND 
 
DEFINITION OF MINCA AND MINOCA 
Previously researchers often used the name myocardial infarction with normal 
coronary arteries (MINCA) and the syndrome had a stricter definition with no 
or minor endo-luminal irregularities without stenosis 8. The first international 
expert paper about the condition was presented in the European Heart Journal 
and the diagnostic criteria for MINOCA included the presence of AMI criteria 
and no coronary artery stenosis ≥50% in any potential infarct-related coronary 
artery on angiography and with no other obvious clinical cause 9. The authors 
concluded that the term MINOCA should only be used as a “working 
diagnosis” in the evaluation of a suspected AMI. The Third Universal 
Definition of Myocardial Infarction, defined the criteria as increased cardiac 
markers of myocardial injury and showing at least one of the following: 
ischemic symptoms, significant ST-T changes, new left bundle branch block, 
development of pathological Q-waves, imaging evidence of new loss of viable 
myocardium or new regional wall motion abnormalities, intracoronary 
thrombus evident on coronary angiography or at autopsy 10.  
 
EPIDEMIOLOGY 
MINOCA is a common diagnosis with a prevalence ranging from 1%-15% 
depending on studied population, thresholds for coronary angiography and the 
definition of coronary artery stenosis 11-19 ( Table 1). According to a recent 
published meta-analysis the prevalence of MINOCA was approximately 6% 
(95% confidence interval (CI), 5%-7%) of all AMI and 40% were women 4. 
These studies revealed all-cause in-hospital and 12-month mortality of 0.9% 
(95% CI, 0.5%-1.3%) and 4.7% (95% CI, 2.6%-6.9%), respectively. In 
Sweden, statistics from The National Board of Health and Welfare showed 
almost 27,000 cases of AMI in 2016, corresponding to 352 cases per 100,000 
inhabitants and year and with a mortality of 25% within 28 days, 
(http://www.socialstyrelsen.se/publikationer2017/2017-10-24 ). We estimated 
at least 21 cases of MINOCA per 100,000 inhabitants and year.  
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Table 1. Epidemiological studies in MINOCA 
Study Year Type of 
study 
Definition 
of 
coronary 
artery 
stenosis 
Study 
group 
mean 
age         
                                 
Study 
group 
female 
gender 
% 
Prevalence 
of 
MINOCA 
 
 
% 
Larsen  
et al 
2005 Prospective 
cohort study 
≥50% 58 40 4.6 
Bugiardini 
et al 
2006 Retrospective 
cohort study 
≥50% 57 52 9.1 
Patel  
et al 
2006 Retrospective 
cohort study 
≥50% 59 57 8.6 
Gehrie  
et al 
2009 Cohort  
Study 
≥50% 59 59 10 
Kang  
et al 
2009 Prospective 
cohort study 
≥50% 59 39 4.4 
Planer  
et al 
2014 Prospective 
cohort study 
≥50% 54 53 8.8 
Lindahl  
et al 
2017 Register  
Study 
≥50% 65 61 4.8 
Smilowitz 
et al 
2017 Register  
Study 
≥50% 54 for 
men 
63 for 
women 
62 5.9 
Barr  
et al 
 
2017 Prospective 
cohort study 
≥50% 57 50 15 
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ETIOLOGY 
 
The MINOCA syndrome comprises several underlying diagnoses that can be 
divided into coronary cardiac disorders, non-coronary cardiac disorders and 
extra-cardiac causes 20. The condition is most likely multifactorial with a 
combination of two or more different mechanisms. For example, a disrupted 
plaque in a coronary segment causing vasospasm or myocarditis as a 
triggering cause for takotsubo syndrome (TS) 21,22 
 
 
 
 
Figure 1. The underlying pathophysiology of MINOCA is multifactorial  
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Coronary cardiac disorders 
 
Plaque disruption  
The term disruption means erosion, ulceration, rupture or intraplaque 
haemorrhage that may occur in non-obstructive coronary lesions or in normal 
portions of the coronary tree. Plaque disruption (PD) is included in type-1 
AMI, even when no thrombus can be found, according to the Universal 
definition document of Myocardial Infarction 10. PD seems to be common in 
MINOCA. Two independent studies using intravascular ultrasound (IVUS) 
identified PD or ulceration in about 40% of patients with MINOCA21,23. 
Plaque morphology and global plaque burden appear to be important factors 
for disruption 24. Another cohort-study using IVUS concluded that no women 
with MINOCA and completely normal arteries was found to have PD 25. The 
location of plaques was different compared to CHD and PD did not typically 
occur at the site of the largest plaque in the vessel. The disrupted plaques in 
that study were more fibrous or fibrofatty, were less outwardly remodelled and 
had a lower percentage plaque burden 25. They concluded that other and better 
techniques with higher resolution such as optical coherence tomography 
(OCT) or integrated backscatter IVUS could characterize the PD sites better 
and in future studies this is needed especially in women with normal coronary 
arteries.  
 
Coronary Artery Spasm 
Coronary artery spasm (CAS), also known as vasospastic or variant angina 
(Prinzmetal angina), predominately occurs during rest and in the midnight to 
early morning hours. The patients are often younger with fewer classical 
cardiovascular risk factors and are more likely to have other vasospastic 
disorders such as Raynaud’s syndrome and migraine headache 26. The reported 
prevalence varies greatly across ethnic populations with a high prevalence in 
Asia and may also be different between cohorts due to difficulties in 
confirming the diagnosis because of daily or monthly variation of disease 
activity 27. This can reflect a vascular smooth muscle hyperreactivity to 
endogenous or exogenous vasospastic substances such as ergonovine, cocaine 
but also due to hyperventilation or exercise 28. Provocative spasm testing has 
demonstrated inducible spasm in 28% of patients with MINOCA within 6 
  6 
weeks post AMI according to 8 studies and could therefore be one of the 
major pathophysiological mechanisms in MINOCA 4. There are also cases of 
CAS and normal coronary arteries described in patients when using 
epinephrine during severe anaphylactic reactions 29 
 
Coronary microvascular dysfunction 
 
Coronary microvascular dysfunction (CMVD) and microvascular 
spasm/angina (previous term: syndrome X) are also potential causes of 
MINOCA since elevated cardiac markers have been detected following spasm 
testing despite the absence of inducible large vessel spasm 30. The 
prevalence of CMVD is thought to be more common among women and there 
are increased long-term risk of cardiovascular events31. The reason for this 
is not fully understood and remains debated. There are theories that women’s 
higher prevalence of luminal plaque erosion may play a role for 
microembolization 32.  Also, different hormone factors, such as the loss of 
oestrogen, may have an impact and probably mediate CMVD through loss of 
nitric oxide (NO) 26. The prevalence of CMVD in the general population is not 
established, as testing for CMVD is difficult/usually not performed. There is 
one study of 80 patients with AMI and non-obstructed coronary arteries on 
angiography who underwent invasive CMVD testing, showing a prevalence of 
30% 33. Coronary flow reserve (CFR) was measured in the same study which 
were lower in patients with suggested CMVD. CFR measures the myocardial 
blood supply and especially the ability of the coronaries to increase blood 
flow under stress. Local infusion of a vasodilating drug, such as adenosine or 
the reactive hyperaemic response can be used to assess CRF 34. A sub-study of 
the Stockholm Myocardial Infarction with Normal Coronaries (SMINC) study 
could not confirm catecholamine (Dobutamine)-induced CMVD in patients 
with takotsubo syndrome (TS). However, a small but significant difference in 
CFR was described at low-dose Dobutamine infusion 35.  
 
Coronary thromboembolism  
The prevalence of coronary thromboembolism in MINOCA is thought to be 
low and perhaps this is due to lack of screening for inherited disorders. 
Thrombosis in AMI can arise due to emboli in plaque disruption or CAS. It 
can also be caused by hereditary thrombophilia disorders including Factor V 
Leiden thrombophilia, and Protein S and C deficiencies. Studies in patients 
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with MINOCA have reported a 14% prevalence of these inherited disorders 4. 
Coronary emboli can arise from the mentioned thrombophilia disorders but 
also because of other hypercoagulable states such as atrial fibrillation and 
valvular heart disease 9. 
 
Spontaneous coronary artery dissection 
Spontaneous coronary artery dissection (SCAD) is defined as spontaneous 
separation of the coronary arterial wall that is unrelated to trauma and 
atherosclerosis. SCAD is considered a rare cause of AMI, constituting 
approximately 0.1%-4% 36. SCAD is common in young women, more than  
90% of cases are reported in women with ACS 26. Predisposing factors are 
connective tissue disease and/or arteriopathy (most commonly fibromuscular 
dysplasia), physical and emotional stress, and changes in the intima-media 
composition due to hormones, pregnancy and delivery. Survival is good but 
major adverse cardiac events are frequent including recurrent SCAD 36.   
 
Myocardial bridging   
Myocardial bridging (MB) is a congenital abnormality characterized by the 
presence of an intramural course of a coronary artery that can give rise to 
systolic flow disturbances. According to a recent published meta-analysis the 
overall prevalence of MB was 19%, in autopsy studies 42%, in CT studies 
22% and coronary angiography studies 6% 37. The authors concluded that 
autopsy studies are the gold standard in evaluating the prevalence of MB and 
that high-resolution CT scanning of coronary arteries should be preferred over 
coronary angiography studies. It has usually been considered as a benign 
condition but there are studies suggesting a potential haemodynamic 
significance of MB and some, usually case reports, indicates a possible 
association between MB and various cardiac pathologies like AMI, left 
ventricular rupture, life-threatening arrhythmias, hypertrophic 
cardiomyopathy, apical ballooning syndrome or sudden death 38. MB is 
suggested to be a possible underlying mechanism for MINOCA but a subset of 
the SMINC-study showed similar prevalence for MB in MINOCA, with or 
without takotsubo syndrome (TS), as in healthy controls 39.  
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Non-coronary cardiac disorders  
 
Takotsubo syndrome  
Many names have been used for TS, that was discovered in Japan three 
decades ago; broken-heart syndrome, takotsubo cardiomyopathy, apical 
ballooning or transient cardiomyopathy. Lately a consensus was reached to 
define a universal name, according to the term cardiomyopathy which should 
be avoided and TS is recommended 40. TS is often but not always the result of 
severe stress. There are two main clinical subtypes; primary or secondary TS, 
depending on the clinical picture and the presence of a major medical 
condition triggering the TS episode 40. The primary form is described as being 
caused by a physical or emotional stressful trigger or as occurring 
spontaneously. Potential co-existing medical conditions may be the 
predisposing risk factors but are not the primary cause of the exacerbation. 
The secondary form is caused in patients already hospitalized for other 
medical, surgical, anaesthetic, obstetric or psychiatric conditions. In these 
patients, sudden activation of the sympathetic nervous system or a rise in 
catecholamines can cause TS. Emotional triggers could be divorce, 
unexpected death of a loved one or troublesome family matters while severe 
acute illness such as severe sepsis, acute anxiety attack/panic disorder or acute 
exacerbation of asthma or chronic obstructive pulmonary disease (COPD)40.  
The pathogenesis of TS is not well understood and probably it involves excess 
of catecholamines and endothelin-1, myocardial stunning and CMVD 41. 
Endothelial dysfunction is an imbalance between vasoconstricting and 
vasodilating factors that might be an important link between stress and 
myocardial dysfunction in TS, since studies have shown that mental stress can 
induce endothelial dysfunction 42. Pre-existing vascular dysfunction can thus 
increase the risk of TS and perhaps trigger the sympathetic nervous system 41. 
 The prevalence of TS in MINOCA varies but according to a recent review 
including 16 CMR studies that were performed within 6 weeks after 
admission, the prevalence was 16% 4. TS often has a similar presentation as in 
AMI with ST-segment changes, elevation of cardiac markers, reversible heart 
failure with myocardial stunning and the absence of occlusive coronary 
arteries. TS predominately affects postmenopausal women (90%) and cardiac 
markers are lower compared to CHD 40. The prognosis has previously been 
expected to be generally good but several studies have lately presented 
   9 
opposite results 43. A recent case-control study from the Swedish Coronary 
Angiography and Angioplasty Register (SCAAR) during 2009-2013 showed 
similar mortality in TS when compared with CHD 44. Also, the International 
Takotsubo Registry (InterTAK registry), comprising 26 centres in Europe and 
the United States compared TS with CHD during 2011-2014 and found similar 
rates of severe in-hospital complications including shock and death 45,46. 
There is no single universally accepted diagnostic definition of TS. The most 
widely used in clinical practice and research is the Mayo Clinic Criteria of TS 
from 2004 which was modified 2008 47,48 and is based on expert consensus 
opinion. The criteria include: 1. Transient hypokinesis, akinesis, or dyskinesis 
of the left ventricular mid-segments with or without apical involvement; the 
regional wall motion abnormalities extend beyond a single epicardial vascular 
distribution; a stressful trigger is often, but not always present. 2. Absence of 
obstructive CAD or angiographic evidence of acute plaque rupture 3. New 
electrocardiographic abnormalities (either ST-segment elevation and/or T-
wave inversion) or modest elevation in cardiac troponin. 4. Absence of 
pheochromocytoma and myocarditis. There are new diagnostic criteria 
suggested by the Heart Failure Association (HFA) of the ESC from 2015 that 
includes recovery of ventricular systolic function on CMR at 3-6 months 
follow-up, elevated NT-proBNP and cardiac troponins in the acute phase. 
Pheochromocytoma is also included as a secondary cause of TS.  
There are also some studies suggesting routine measurement of other cardiac 
biomarkers, such as NT-pro-BNP and markers of stress like catecholamine 
and cortisone to differentiate TS from AMI. One study could demonstrate that 
patients with STEMI had lower NT-pro-BNP levels and greater elevations of 
troponin T and CK-MB, compared to the TS group. Catecholamine and 
cortisol levels were not elevated in patients of TS, suggesting that routine 
measurement of these stress hormones is unlikely to be of diagnostic value in 
clinical practice 49. 
There are anatomical variants of TS, with three more common and several rare 
anatomical variants. The apical, with or without mid-left ventricular variant, is 
estimated to have of  a prevalence of up to 80% (Figure 2), only mid-left 
ventricular of 10-15% (Figure 3) and inverted or basal of around 5% 40. There 
are clinical challenges in differentiating TS from myocarditis and CHD and 
milder forms of TS with rapid recovery that are misdiagnosed probably also 
exist 47. 
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Figure 2. Classical takotsubo syndrome. Diastolic and systolic freeze frames from a left ventriculogram 
illustrating hyperdynamic basal contraction and akinesis of the mid and apical segments (arrows). 
 
Figure 3. Only mid-left ventricular takotsubo syndrome. Diastolic and systolic freeze from a left 
ventriculogram with apical sparing variant of takotsubo syndrome. Function at the base and apex is  
preserved with akinesis of the mid segments (arrows).  
 
 
Myocarditis  
Myocarditis is common in MINOCA. The clinical presentation varies widely 
from one patient to another but often mimics the symptoms of AMI including 
ECG-changes and elevation of cardiac troponins. According to the 2013 ESC 
Task Force the definitive diagnosis can only be achieved by endomyocardial 
biopsy 50,51. However, this is not a routine clinical practice and current 
guidelines recommend this only in a limited number of clinical cases that do 
not include common presentations of myocarditis, especially pseudoinfarction 
52. The aetiology often remains undetermined but a large variety of infectious 
and systemic diseases including drugs and toxins can cause myocarditis. Half 
of the patient with myocarditis recover within 4 weeks but the risk of 
developing persistent heart failure is 25% which can progress to end-stage 
dilated cardiomyopathy with a need of heart transplantation 50. 
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The prevalence depends on study design and is about 33% in MINOCA 
according to a recent meta-analysis of 5 studies 53. The authors concluded that 
young age and high CRP were associated with myocarditis and they also 
highlighted the importance of using CMR in MINOCA to achieve the correct 
diagnosis and treatment. Another CMR study confirmed that myocardial 
fibrosis was more frequent in men and in patients younger than 40 and that the 
injury appears to be more regional and more severe in these cases 54. 
 
Extracardiac disorders 
Pulmonary embolism (PE) is often misdiagnosed as AMI with similar clinical 
presentation and with elevated cardiac troponins 55. It is important to exclude 
PE with the help of D-dimer testing, computed tomography of the pulmonary 
arteries or ventilation/perfusion scintigraphy of the lungs 56. There are also 
other conditions such as stroke, acute renal failure and adult respiratory 
distress syndrome that can be the cause for onset of MINOCA 57 .  
Other forms of secondary AMI to consider includes anaemia, tachy-brady-
arrhythmia, hypotension, shock, severe hypertension with or without LV 
hypertrophy, severe aortic valve disease, heart failure, cardiomyopathy, effects 
of toxins (e.g. sepsis) and pharmacological agents (e.g. catecholamines) 58. 
Secondary or type 2 AMI is defined as myocardial cell necrosis due to supply-
demand mismatch, characterized by significant increase and/or decrease in 
troponins with at least one value above the 99th percentile of a normal 
reference population in the absence of evidence for coronary plaque rupture in 
addition to at least one of the other criteria for AMI 10. Factors of myocardial 
oxygen demand include systolic wall tension, contractility and heart rate while 
myocardial oxygen supply is conveyed by coronary blood flow and oxygen 
content. Type 2 AMI is a clinical challenge and lately often detected since 
more high-sensitivity cardiac troponin assays are used in the clinics 58 
 
CLINICAL CHARACTERISTICS   
Patients with MINOCA are usually younger with different sex distribution 
including more women compared to patients with CHD. The cardiovascular 
risk factors in MINOCA are similar as in CHD except for a more favourable 
lipid profile 4. Symptoms and ECG findings in this syndrome are similar 
regardless of underlying causes, and troponin markers tends to be lower 
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compared to CHD. The probability of MINOCA is similar between ECG with 
or without ST segment elevation for women, and lower in NSTEMI than 
STEMI among men 9. A recent study revealed similar marital status, 
postsecondary education, work status, and household-income in patients with 
MINOCA as in patients with CHD 59. 
 
CLINICAL MANAGEMENT  
Lately several algorithms have been developed to help clinicians to assess 
MINOCA 4,60,61. When coronary angiography shows no stenosis ≥ 50%, a left 
ventriculogram should be performed to describe the distributions of regional 
wall motion abnormalities. At this stage MINOCA should be handled as a 
“working diagnosis” 9. PE should be excluded by using D-dimer testing and 
when there is further need of investigation by using computed tomography of 
the pulmonary arteries or ventilation/perfusion scintigraphy of the lungs. CMR 
is highly recommended in MINOCA and plays a crucial role in identifying 
myocarditis, areas of myocardial damage and other underlying causes. 
Myocarditis should be established early in the algorithm, maybe even before 
coronary angiography 9.  
Figure 4. Recommended diagnostic algorithm for MINOCA  
 
 
 
 
 
 
 
 
 
 
From: ESC working group position paper on myocardial infarction with non-obstructive coronary arteries Eur 
Heart J. 2016;38(3):143-153. doi:10.1093/eurheartj/ehw149 
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TREATMENTS AND SECONDARY PREVENTION IN MINOCA 
Since MINOCA is not a disease but a clinical syndrome with different 
pathophysiological mechanisms there is no single treatment modality. A 
recent observational study indicated long-term beneficial effects on outcome 
in patients with MINOCA with statins and ACEI/ARBs and a trend toward 
positive effects of β-blocker and a neutral effect of dual anti-platelet therapy 
17. There is also experimental evidence that increased sympathetic activation is 
of importance for the occurrence of cardiovascular events, and therefore β-
blocker treatment after AMI due to CHD might be beneficial 62. In MINOCA 
patients, some authorities recommend treatment with β-blockers, mostly based 
on theoretical considerations 63. On the other hand, some observational studies 
in patients with either cardiovascular risk factors only or known prior AMI, 
known CHD without AMI and in patients with TS have failed to show long-
term beneficial effects of β-blocker treatment on cardiovascular events 46,64. In 
the TS study mentioned above, the use of ACEI/ARBs was associated with 
improved survival at one year 46. Generally, patients with MINOCA are 
discharged from the hospitals without any follow-up management. One recent 
study showed that achievement of secondary prevention targets such as blood 
pressure and LDL cholesterol levels, non-smoking and exercise training are 
associated with a prognostic benefit in patients with MINOCA similar to 
patients with CHD 65.    
 
PROGNOSIS AND RECURRENT EVENTS  
In general, the prognosis for patients with MINOCA is relatively good, with 
12-month mortality around 5%, which is lower than in patients with CHD 4.  
One study of 2 438 patients evaluating the long-term outcome of patients with 
MINOCA compared to CHD found a similar risk of major adverse cardiac 
event 66. The authors concluded that patients with MINOCA remain at high 
risk of long-term recurrent ischemic events. Another study performed between 
2011-2013 compared MINOCA that was classified as AMI type 1 with AMI 
type 2 and they found similar risk profiles, extent of necrosis and long-time 
prognosis regarding mortality risk 67. 
The recurrence of the MINOCA syndrome has previously not been studied. 
There are some case reports of recurrent symptoms in patients with MINOCA, 
suggesting further investigation to define the cause and potential treatment of 
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symptoms 68. Recently a study that followed 114 patients with TS during 
2003-2015 confirmed recurrence of TS in seven cases (6.1%) and the time 
interval between the index event and its recurrence varied from six months to 
six years. Hypertension, COPD and/or asthma increased risk for relapse 69. 
The authors concluded that TS recurrence should be the first differential 
diagnosis in patients with a history of TS. These findings are difficult to apply 
to all patients with MINOCA due to different underlying causes. On the other 
hand, since TS and CMVD are both known to reoccur one can speculate that 
this can appear in all cases. 
  
MINOCA AND CMR IMAGING 
CMR imaging has become an important tool in cardiology. The non-invasive 
technique is complex and newer therapeutic applications are constantly being 
developed. It can be used to assess ventricular volumes, masses and function. 
CMR can define cardiac anatomy and structure, quantify myocardial perfusion 
and measure blood flow 70.  The late gadolinium enhancement (LGE) 
technique images the myocardial tissues and can differentiate ischemic from 
non-ischemic causes of injury 71-73. The contrast that is used in LGE is 
Gadolinium (Gd) which accumulates in the extracellular space. In fibrotic 
non-viable myocardium, the extracellular volume increases and the contrast 
accumulates and washes out slowly 73. About ten minutes after contrast 
injection, an inversion recovery (IR) sequence is used to detect remaining 
contrast in the myocardium. In an infarcted area (scar) contrast media 
enhances the signal. Healthy myocardium has a low signal, if the correct IR-
time is chosen 71,72. CMR can differentiate between diagnoses included in 
MINOCA such as TS and myocarditis and can also establish if a sub-
endocardial or transmural AMI has occurred74.  
One recent systemic review of 16 publications that performed CMR within 6 
weeks after the event showed that an underlying diagnosis for MINOCA was 
found in nearly 80% of the cases. The results showed subendocardial infarction 
in 24% , myocarditis in 38%, TS in 16% and 21% patients with normal CMR 4. 
There are several studies, mostly retrospective, that used CMR in MINOCA 
with similar results regarding myocardial infarction (16-26%) but great 
variation regarding myocarditis (27-54%) and normal cardiac MRI (0-30%) 74-
82. The time from coronary angiography to CMR is probably of importance and 
varied between 3-10 days in these studies (Table 2). There are some 
disadvantages with CMR such as long scanning time, and it is not feasible for 
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all patients for instance those with metal clips, cardiac devices and severe 
claustrophobia. The advantages of CMR are the non-invasive procedure, the use 
of non-toxic contrast agents and the three dimensional imaging capacity 70 
 
 
Table 2. CMR studies and the detection of underlying diagnosis in MINOCA 
 
Study Year of 
publication 
Type of study Patients 
included 
Median 
time from  
angiogram 
to CMR 
(days) 
CMR 
provides 
a 
diagnosis 
% 
Laraudogoitia  
et al 
   2009 Retrospective 80 3 95 
Leurent  
et al 
   2010 Prospective 107 5 90 
Gerbaud  
et al 
   2011 Prospective 130 6 76 
Chopard  
et al 
   2011 Prospective 87 10 63 
Emrich  
et al 
   2015 Retrospective 125 3 90 
Pathik  
et al 
   2016 Prospective 125 6 87 
Camastra  
et al 
   2017 Retrospective? 190 4 85 
Panovsky  
et al 
   2017 Retrospective 136 Lacking 92 
Dastidar  
et al 
   2017 Retrospective 204 7 70 
 
ATHEROSCLEROTIC AND INFLAMMATORY MARKERS IN HEART DISEASE  
Biomarkers 
There is evidence that inflammation contributes to the initiation and 
progression of atherosclerosis. High-sensitivity C-reactive protein (hsCRP) is 
an acute-phase reactant that measures subclinical systemic inflammation 83. It 
is not clear whether inflammation simply is a result of the atherosclerotic 
process or if it is a major driver. Inflammation also gives raise to 
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dyslipidaemia with elevated low-density lipoprotein cholesterol (LDL-C), 
triglycerides and reduced high-density lipoprotein cholesterol (HDL-C). The 
cut-off point for hsCRP is challenging due to gender and racial/ethnic 
differences. For instance, African Americans have significantly higher hsCRP 
levels than white Americans and females have higher baseline levels than do 
men (43,44). In the large Jupiter study, patients with normal LDL-C and high 
hsCRP were treated with statin with reduction in cardiovascular events and 
20% reduction in all-cause mortality 84,85. The trial demonstrated that hsCRP 
was an independent risk factor for treatment with statin and was associated 
with significant lowering of hsCRP (37%). 
Assessment of brain natriuretic peptides (BNP) is recommended by guidelines 
for diagnosis and management of patients with heart failure. BNP is a 
precursor secreted by myocytes during periods of increased ventricular stretch 
and wall tension. On secretion, the propeptide is split into the biologically 
active peptide and the more stable N-terminal fragment BNP (NT-proBNP) 
which is believed to be involved in the regulation of blood pressure, blood 
volume, and sodium balance 86. We also know that NT-proBNP is a marker of 
vascular remodelling but it is unclear to what extent it can be used in 
prediction of CHD. The NT-proBNP is almost always significantly elevated 
during acute TS and some evidence suggests that NT-proBNP is a more useful 
diagnostic biomarker than troponin 87. Therefore, elevated natriuretic peptide 
levels were included in the new diagnostic criteria for TS proposed by the 
HFA association of the ESC 40. Recent published data also showed that 
admission NT-proBNP is an independent predictor for short and long-term 
adverse events in TS patients and could be used as a marker for risk 
stratification immediately at presentation 88,89. 
Non-invasive methods to measure early atherosclerosis. 
Endothelial function  
The endothelium is not a simple monolayer of cells separating flowing blood 
from the vascular wall, it is also important for the vascular homeostasis. NO is 
the principal mediator of endothelial function being a potent vasodilator, 
inhibiting platelet aggregation, vascular smooth muscle cell migration and 
proliferation, and monocytes adhesion. Cardiovascular risk factors promote 
the endothelial dysfunction which is described as impairment of vasodilation, 
plaque progression and vulnerability 90,91. In the beginning endothelial 
function was measured invasively during cardiac catheterization 92. Today, 
several non-invasive methods are used to measure reactive hyperaemia such as 
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brachial artery flow-mediated vasodilation of brachial artery (FMD) and 
endothelial peripheral arterial tonometry (Endo-PAT) 93. The Endo-PAT 
technique is less operator-dependent and uses the contralateral arm as its 
internal control to correct for systemic changes during testing 94. Both methods 
are based on the same principle of reactive hyperaemia phenomenon. That is, 
increased blood flow following a period of transient arterial occlusion, which 
serves as an index of endothelium-dependent vasodilator function (Figure 5). 
FMD assesses the endothelial response to shear stress in the brachial artery as 
a result of hyperaemia, whereas Endo-PAT measures the actual hyperaemia 94. 
 
Figure 5. Typical recordings from the EndoPat.  
 
 
Estimation of peripheral arterial tonometry (PAT) ratio after correction of the reactive hyperaemia index for the control 
arm. Probe 1 corresponds to the occluded arm and probe 2 to the control arm. The blue-coloured interval corresponds to 
the duration of occlusion in the test arm. 
Intima-media thickness 
Another commonly used non-invasive method to measure early 
atherosclerosis is intima-media thickness (IMT). Previous studies have shown 
cross-sectional associations between IMT and cardiovascular risk factors, the 
prevalence of cardiovascular disease and the involvement of other arterial 
beds with atherosclerosis 95. In the MESA (Multi-Ethnic Study of 
Atherosclerosis) study, IMT measurements were used as a surrogate for 
subclinical cardiovascular disease and as a variable predictive of 
cardiovascular events. IMT measurements of the common carotid artery were 
available in more than 99% of the MESA population and were predictive of 
cardiovascular events. More importantly, IMT and plaque thickness 
measurements made in the internal carotid artery and carotid bulb were also 
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available in more than 98% of the study group and plaques were strongly 
predictive of cardiovascular events 95. 
Figure 6. An example of a common carotid artery image  
 
The key interfaces used to measure common carotid artery intima-media thickness are the lumen-intima  
and the media-adventitia interfaces. The distance between these 2 interfaces is the intima-media thickness. 
 
QUALITY-OF- LIFE IN PATIENTS WITH HEART DISEASE 
Assessment of health-related quality-of-life (QoL) is an important and very 
useful health outcome especially in patients with chronic diseases like CHD 
and heart failure 96-98. The definition of patient-reported outcome measurement 
(PROM) is “any report of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patients response by a 
clinician or anyone else” 99. The definition of QoL is more unclear and means 
different things to different people 100. Universally accepted definition is up to 
date lacking. There is one suggested integrative definition of QoL that 
combines measures of human needs with subjective well-being or happiness. 
QoL is proposed as a multiscale, multi-dimensional concept that contains 
interacting objective and subjective elements. They related QoL to the 
opportunities that are provided to meet human needs in the forms of built, 
human, social and natural capital (in addition to time) and the policy options 
that are available to enhance these opportunities 101.  
Patient-reported health status can be used as a complement to the traditional 
outcomes such as cost-of-care, hospitalization, cardiovascular events, 
mortality. QoL instruments can inform and evaluate the impact of a disease on 
general well-being, satisfaction with care and the benefits of medical 
interventions 96,102. Despite this, surveys to assess patient-reported health 
status are underused in clinical practice 96.                                                                                                                                                                                                                                                                                                                                                                                                                                            
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When QoL is used in patients with CHD, it should comprise a disease-specific 
measure in addition to a generic measure 103,104. The most widely used generic 
measures are the medical outcome study 36-Item Short-Form Health Survey 
(SF-36) and the Euro Quality of Life Scale (EQ-5D) and both are standardized 
and validated instruments. The most common disease specific instrument that 
is used in CHD is Seattle Angina Questionnaire (SAQ) 103. 
Studies of patients with MINOCA and their QoL including control groups are 
lacking. However these patients are particularly vulnerable to anxiety and 
depression because few health providers offer psychological support or see 
such support as necessary when the results of a diagnostic procedure are not 
clinically significant 105. Previously, low-vitality scores of SF-36 have been 
shown in chronic diseases such as chronic heart failure, where they were 
associated with fatigue and lower energy, readmission to hospital, inability to 
work, and negative outcomes, such as mortality 106. In patients with CHD who 
underwent rehabilitation, low QoL was associated with greater fatigue and 
decreased exercise capacity, independent from mental distress and CHD 
severity score 107. One recent review found that most cardiac rehabilitation 
programmes, education and counselling sessions, and other psychological and 
cognitive interventions improve QoL and exercise capacity in patients with 
CHD 7.  
There are few studies on the long-term effects of uncertainty and associated 
health-related QoL in patients with heart disease. One study in patients with 
chest pain/angina waiting for elective angiography showed that high baseline 
uncertainty prior to angiography was associated with anxiety and depression 
and lower levels of perceived control and health-related QoL one year after 
coronary angiography, despite the angiographic findings and the treatment 
regimen 6. They concluded that even a patient with normal coronary arteries is 
likely to experience marked reductions in QoL. A few studies have indicated 
that uncertainty is an important part of the experience of cardiac disease 
including those recovering from coronary-artery-bypass grafting or heart 
failure. In these studies higher levels of uncertainty correlated with lower QoL 
108,109. There is one study of interviews in 14 TS female patients at day one and 
9 months after hospitalization pointing out the importance of early diagnosis 
to increase well-being. Initially patients struggled with confusion and 
insecurity concerning their diagnosis, future expectations, prevention, medical 
treatment and follow-up110. When the diagnosis of ACS was disapproved, a 
response of relief was expressed based on TS being a more favourable 
diagnosis, restoring certainty.  
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AIMS 
 
The overall aim of this study is to identify the different underlying causes of 
MINCA with focus on prevalence and to describe risk factors including 
physical and mental health. The ambition is to better understand and handle 
this group of patients. 
 
Hypotheses 
1. CMR imaging can help us to separate different underlying causes of 
MINCA.  
2. Patients with MINCA do not have generalized atherosclerosis.  
3. Patients with MINCA have a poor QoL.  
4. Patients with MINCA including TS have a high prevalence of anxiety and 
depression.  
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MATERIAL AND METHODS 
 
DESIGN AND STUDY POPULATION 
This thesis is based on one case-control study: the SMINC study. The study 
was ongoing for a period of four years (2007-2011) and all patients were 
screened at five coronary care units in the Stockholm metropolitan area 
(Figure 5). According to RIKS-HIA, the total number of patients with ACS in 
the same area at this time span was 4412. 
  
Figure 7. Study flow chart in the SMINC study 
 
  
 
The inclusion criteria were patients between 35 and 70 years of age fulfilling 
the diagnostic criteria of acute myocardial infarction, sinus rhythm on ECG 
and a coronary angiogram with no or minimal signs of atheromatosis. Minimal 
atheromatosis was defined as small irregularities in the coronary vessel wall, 
giving rise to <30% reduction of the vessel lumen with all coronary 
angiograms independently examined by a second angiographer. Acute 
myocardial infarction was diagnosed according to the ESC/ACC/AHA 
universal definition of myocardial infarction 10 and the diagnosis of TS was 
All MINCA 2007-2011
n=277
Patients screened in SMINC study
n=176
CMR-imaging
n=152
Patients included in SMINC study
n=100
Follow-up
from 6 weeks to 3 months
Study I 
 
 Study II, III & IV 
Study II 
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based on the Mayo Clinic diagnostic criteria 47. The exclusion criteria were 
patients with pacemaker, a previous myocardial infarction or cardiomyopathy, 
serum creatinine >150, previous and advanced chronic obstructive pulmonary 
disease, pulmonary embolism and myocarditis. Matching patients with CHD 
were recruited during their hospital stay or at follow-up at the respective 
coronary care unit. Healthy controls were recruited from the Swedish 
Population Registry (2007-2008) or from the computer-based medical record 
system Take Care® containing all citizens in Stockholm (2009-2012). The 
controls were selected randomly by date of birth and gender to match cases 
and contacted for participation by an invitation letter followed by a telephone 
call.  
 
SCREENING-PHASE OF SMINC-STUDY 
The first 100 patients underwent computed tomography (CT) of the pulmonary 
arteries to exclude PE. The case record form (CRF) protocol was changed to  
D-dimer testing after 100 negative CTs. CMR imaging was performed in 152 
patients mainly to exclude myocarditis. After the screening-phase 100 patients 
with MINCA were included in the SMINC study and individually matched by 
gender and age to the two control groups. Symptoms, clinical findings and 
medication were registered in the CRF. The initial routine clinical chemistry 
and ECG were acquired from medical records and further blood-sampling was 
taken during follow-up 3 months after admission.  
CMR imaging 
CMR imaging protocol 
The standard CMR imaging protocol included standard steady-state free 
precession (SSFP) cine imaging, T2-weighted oedema imaging and LGE for 
fibrosis detection. The protocol differed slightly between the different sites. 
The investigation was performed in the supine position with a cardiac coil 
using one of three 1.5 T systems (General Electric Healthcare; Signa Excite 
Twin-Speed, Waukesha, WI, USA; Siemens Sonata, Erlangen, Germany; and 
Philips Intera CV, Best, the Netherlands) during vector ECG monitoring. The 
imaging protocol included scout imaging, localization of the short axis and 
then covering of the whole left ventricle (LV) 1.6-3.3 ms, repetition time (TR) 
2.8-3.6 ms, flip angle 60°, 25 phases, 8 mm slice, no gap, matrix 160–226 x 
141–226 and T2-weighted triple inversion recovery (TE) 60–80 ms, TR two 
R–R intervals, TI 150–170 ms, slice thickness 8 or 14 (14 mm with GE 
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TwinSpeed), gap 8 mm, flip angle 90–180°, matrix 226–256 x 226–256) 
images were acquired in the same long- and short-axis planes. LGE images 
were acquired 15–20 min after contrast injection of intravenous gadolinium-
DTPA (0.2 mmol kg-1) using a 2D or 3D (3D with Philips Intera CV) 
inversion recovery gradient echo sequence (TE 1.1–3.3 ms, TR 3.8–7.0 ms, 
inversion time 180–300 ms to null the signal of myocardium, 8 mm slice, no 
gap, matrix 240–256 x 180–192) in the same slice orientation as cine SSFP 
images. Each slice was obtained during end-expiratory breath holding. Two-, 
three- and four-chamber views were also obtained to confirm the findings. 
CMR imaging analysis 
All CMR images were analysed using offline, freely available segmentation 
software (SEGMENT V.1.8 R1405; http://medviso.com/segment.se/ ). The 
CMR images were examined and interpreted by two independent experienced 
experts blinded to all clinical data and the imaging report from the 
investigating hospital, thereby minimizing interhospital variation. In case of 
disagreement, a third CMR imaging specialist was consulted for consensus. 
End-diastolic and end-systolic volumes were measured in the phase with the 
largest and smallest LV volumes, respectively. LV ejection fraction, stroke 
volume and LV mass were calculated on cine SSFP sequences using manual 
delineation of the endocardial and epicardial borders including papillary 
muscles and trabeculations when contiguous with the LV. To calculate 
LVmass, the myocardial volume was multiplied by the density of myocardial 
tissue (1.05 g mL-1). All volumes were determined relative to body surface 
area. T2-weighted images were visually examined to detect areas of high 
signal compatible with oedema. LGE images were assessed for subendocardial 
enhancement in the distribution of a coronary artery suggesting myocardial 
infarction, or midwall/subepicardial enhancement suggesting myocarditis. 
Patients with patchy involvement on LGE (intramyocardial, including both 
subepicardial and subendocardial) were considered to have myocarditis. 
Images showing normal volumes and function and with no LGE or T2-
weighted abnormalities were considered to be “normal CMR images”. 
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FOLLOW-UP MEETING IN SMINC-STUDY 
 
During a follow-up visit 3 months after the acute event, several investigations 
were performed such as blood samples, non-invasive atherosclerosis 
measurements, bicycle stress test and completion of several surveys.  
 
Laboratory tests 
There were many different blood samples that were taken during the 3 months 
follow-up visit. In current thesis we will only focus on NT-proBNP. 
NT-proBNP  
Measurement of circulating levels of BNP or NT-proBNP has been 
recommended in the diagnosis and prognosis of patients with symptoms of left 
ventricular dysfunction and for stratification of risk in patients with AMI 111. 
However there are some clinical conditions such as diabetes mellitus, obesity, 
renal insufficiency and anaemia that also can elevate NT-proBNP without 
established cardiovascular disease 86,111,112. The cut-off or  “normal” NT-pro-
BNP is not clear but there are two studies in normal subjects without 
cardiovascular disease or LV-dysfunction that found increased levels with age 
and women (13,14).  
 
Non-invasive measurements of atherosclerosis 
Endothelial function test 
Endothelial function was measured 3 months after the acute event with 
EndoPAT® (Itamar Medical Ltd), a specialized device for assessment of 
endothelial function. The system is based on peripheral arterial tone (PAT) 
signal technology; a non-invasive plethysmographic method measuring 
pulsatile volume changes in the digital bed. The test is user-independent and 
calculates automatically. The test was performed in a thermoneutral and quiet 
surrounding avoiding pre-test consumption of caffeine and smoking. The test 
quantifies endothelium-mediated changes in vascular tone elicited by a five-
minute occlusion of the brachial artery using a standard blood pressure cuff 
inflated to a supra-systolic pressure. When the cuff is deflated, the surge of 
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blood flow causes an endothelium-dependent flow-mediated dilatation leading 
to reactive hyperaemia and an increase in the PAT signal amplitude. Values 
from the contralateral probe are used as a control for non-endothelial-
dependent changes in vascular tone. The post-to-preocclusion ratio, called 
EndoScore or RHI, is calculated with specialized software 113,114 (Figure 5).  
Intima-media ultrasound 
Two-dimensional images of the left and right common carotid artery (CCA) 
were acquired, using an ultrasound scanner (Vivid 7; General Electric (GE), 
New York) equipped with a 12-MHz transducer, 3 months after the acute 
event. From each CCA, a long-axis cine loop of 3 beats and 3 diastolic images 
at the time of the ECG R-wave were stored digitally on magnet-optic discs for 
offline analysis. The IMT of the CCA far wall was measured in 3 diastolic 
images from each side using GE semiautomatic IMT analysis software. A 10-
mm region of interest was manually placed starting 1 cm proximal to the 
carotid bulb. The intima media borders of the far wall, toward the lumen and 
the adventitia, were identified automatically by the program. Manual 
correction was not performed, and in the case of suboptimal tracking, the 
region of interest could be adjusted somewhat or another diastolic frame 
chosen. IMT was calculated as the mean of 3 semiautomatic measurements  
115. A mean of the results of IMT of the left and right CCA was calculated and 
used for comparison between the groups.  
 
Exercise bicycle stress test 
Patients with MINOCA and CHD controls performed a standardized exercise 
bicycle stress test 6-12 weeks after the acute event, whereas the healthy 
controls performed it at their one and only study visit. Subjects performed a 
symptom-limited exercise stress test using a modified protocol starting at 40 
Watts (W) by addition of 10 W every minute. The test included an observation 
time of 10 minutes rest after the test to identify any possible post-stress 
symptoms and ECG changes including arrhythmias. During exercise, blood 
pressure, degree of subjective limitations like chest pain, effort, and breathless 
using the Borg score were monitored every minute. The predicted heart rate 
maximum was calculated using the traditional 220 minus age equation. Work 
capacity was measured in W, and results were presented as maximal work 
capacity and percentage of maximal heart rate.  
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Questionnaires measuring QoL, depression and anxiety 
The SF-36 standard Swedish, version 1.0, was administered 3 months after the 
acute event in patients with MINCA and CHD controls and at the one and 
only study visit for the healthy controls 116. SF-36 is a self-assessment health 
status questionnaire containing 36 items (questions) about sociodemographic, 
health, and personal behaviour, grouped into 8 multi-item domains, measuring 
the following: 1. physical functioning (10 items), 2. social functioning (2 
items), 3. role limitations because of physical problems (4 items), 4.  role 
limitations because of emotional problems (3 items), 5. mental health (5 
items), 6. energy and vitality (4 items), 7. bodily pain (2 items), and 8. general 
health perception (5 items). Two summary measures, a physical component 
summary (PCS) score and mental component summary (MCS) score, are 
constructed from the 8 scales 117. One single item inquired about change in 
health in the last year. Each of the scores for the domains were coded, and 
summed in an Excel chart, and later on transformed in the statistical program 
SPSS and the results presented from 0 (worst possible health) to 100 (best 
possible health). 
The Beck depression inventory (BDI) and Hospital anxiety and depression 
scale (HADS) were administrated at the 3-month visit after the acute event, or 
at the first and only visit for the healthy controls. BDI and HADS are  
commonly used and validated screening tools for anxiety and depression in 
patients with AMI  118,119. BDI is a 21 question multiple choice questionnaire 
that measures severity of depression 120. There are three versions of BDI, the 
original BDI-I, the revised BDI-IA and the current version of BDI-II. In this 
study we used a Swedish version of BDI-I. Each question has four alternatives 
that are scored 0-4 points, giving a maximal score of 63 points. Scores can be 
categorized into normal (0-9), mild depression (10-18), moderate depression 
(19-29) and severe depression (30-63). Participants were asked to rate how 
they had been feeling for the last week.  
We used the Swedish version of HADS that contains 14 items 121. Seven of the 
items relate to anxiety (HADS-A) and seven relate to depression (HADS-D). 
Each question has four alternatives that are scored 0-3 points, giving a maximal 
score of 21 points on each subscale. Scores can be categorized into normal (0-
7), mild (8-10), moderate (11-14) and severe (15-21) anxiety/depression. 
Importantly the inventors created this survey to avoid somatic symptoms, such 
as pain, fatigue and insomnia that could interfere with the mental status. The 
subject are instructed to reply about their feelings during the past week 122. 
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STATISTICAL METHODS 
 
Baseline data in all four studies are presented as mean ± standard deviation or 
median with interquartile range (IQR) in figures if numerical and as percent if  
categorical. Group-wise comparisons were made by Mann-Whitney u test 
(two groups) or Kruskal-Wallis (several groups) for continuous variables. A 
chi2 test was used for categorical data. A p-value < 0,05 was considered 
significant. For computations a software from IBM was used (SPSS statistics 
for Macintosh, versions 20 and 23.0 (IBM, Armonk, NY). 
 
ETHICAL CONSIDERATIONS 
For inclusion, patients were asked to give written informed consent. Each           
patient was assigned a study identification number and a record for 
identification was established. In the screening phase of the study 100 patients 
underwent CT of the thorax to exclude pulmonary embolism and all of them 
turned out to be negative. In this situation we did not find it ethical to proceed 
with further CT thorax due to risk of radiation and thus the protocol was 
changed to only primarily D-dimer. Discomfort during CMR examination is 
common and this was reduced by providing eye mask and music. Patients 
were also able to communicate if any discomfort appeared during the 
examination. If necessary, they also were given sedating medications to be 
able to perform the examination. The one´s with severe claustrophobia (9 
patients) were excluded from the study. During the 3 month follow-up 
meeting we might have increased the stress for all our participants in the study 
by different non-invasive tests including different QoL surveys that took time 
to fill out. In addition, some of the participants could have experienced painful 
moments and fear during the withdrawal of blood samples and during the five 
minute occlusion of one arm when measuring the endothelial function. An 
experienced nurse and a doctor were available for help during the tests. We 
believe that the benefits of the study providing us with information about the 
MINCA population are greater than any potential risk of causing patients any 
discomfort. 
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RESULTS AND SPECIFIC DISCUSSION 
 
 
STUDY I: Myocardial infarction with normal coronary arteries is common and 
associated with normal findings on cardiovascular magnetic resonance 
imaging: results from the Stockholm Myocardial Infarction with Normal 
Coronaries study 
During the inclusion time that lasted between 2007 and 2011, 176 patients 
from the Stockholm metropolitan area with MINCA were screened. According 
to the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) 
277 patients were found with MINCA in Stockholm during this period, 
meaning that 64 % of all patients with MINCA were included in the screening 
phase (Figure 7). The estimated prevalence of MINCA according to the 
number of ACS from RIKS-HIA during this time, was 6%,  and most probably 
this is an underestimate since TS is not recorded as AMI. 
 
CMR imaging results 
A total number of 152 MINCA patients were able to undergo CMR. The 
remaining 24 patients did not undergo CMR due to lack of availability of 
magnetic resonance imaging (MRI), claustrophobia or other reasons.  
In 102 MINCA patients CMR was found to be normal. Twenty-nine patients 
(19%) showed signs of myocardial necrosis and 11 (7%) had signs of 
myocarditis. There were also 10 cases of undetermined CMR findings (7%) 
(Figure 8). The CMR was performed a median of 12 days (6-28 days) after the 
acute event. In our study we found the underlying diagnosis in 26% of all 
CMR examinations. Among patients with a normal CMR, 33 (32%) patients 
were found to have a clinical diagnosis of TS including reversible LV 
dysfunction. As a result of using CMR-imaging the initial clinical diagnosis 
was changed in 65% of the cases. 
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Figure 8. Results of CMR imaging in MINCA 
 
 
 
Compared with other CMR-studies in MINOCA (Table 2) that performed an 
earlier CMR with median time between 3-10 days, a smaller number of patients 
were able to get their underlying diagnosis (26% vs 70-90%). In these other 
studies, the rates of patients with myocardial necrosis and TS in MINOCA were 
similar to our study but with great variations in the rates of myocarditis and 
normal findings on CMR. Reasons for this could be that the CMR techniques 
and protocols has improved since our study was completed. We also excluded 
patients younger than 35 years which might be reflected in our lower rate of 
myocarditis compared to other studies (7% vs 38%). The poor harmony 
between the clinical and the CMR-based diagnosis (65%), as mentioned above, 
is in line with other CMR-studies in MINOCA. One study showed that 54% of 
the patients with MINOCA received a new diagnosis and 41% of them also had 
a management change after using CMR 79. Our conclusion is that CMR is of 
great importance in the search of underlying diagnosis in patients with 
MINOCA. In addition, using CMR earlier after the event and with the latest 
techniques will most likely increase the number of patients in MINOCA with a 
correct diagnosis. 
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STUDY II: Risk factors and markers for acute myocardial Infarction with 
angiographically normal coronary arteries 
A total number of 100 patients with MINCA were included into the SMINC-
study. Patients with myocarditis were excluded by CMR (Figure 7). The mean 
age of all patients and controls was 58 to 59 years and women were 
predominant (72%). One quarter of the patients with MINCA (25%) fulfilled 
all Mayo Clinic diagnostic criteria for TS 47. Another 19% had a less 
prominent abnormal ventricular wall motion on imaging with left 
ventriculography or echocardiography, indicating a possible TS in regression 
or a milder state. All patients with TS were women (Table 3). 
Table 3.  Baseline characteristics of MINCA compared to CHD and healthy controls.  
 MINCA CHD Healthy control MINCA vs 
CHD 
(p-value) 
MINCA vs 
control 
(p-value) 
Age (yrs) 58 ± 8 59 ± 8       59 ± 8 n.a. n.a. 
Women (%) 72 72 72 n.a. n.a. 
BMI (kg/m2) 26 ± 5 27 ± 5 25 ± 4 0.037 0.557 
Heart rate (bpm) 74 ± 15 75 ± 14          69 ± 15 0.706 n.a. 
Systolic blood 
pressure (mm Hg) 
147 ± 27 149 ± 27 128 ± 17 0.492 n.a. 
Troponin ratio* 110 ± 176 275 ± 560 - 0.642 n.a. 
CRP > 5 µg/L  
(%) 
16 13 5 0.699 0.010 
Smoker (%) 21 33 7 0.056 0.004 
Ex-smoker (%) 29 34 40 0.447 0.102 
Hypertension (%) 37 46 17 0.196 0.001 
Hyperlipidaemia 
(%) 
9 20 4 0.027 0.152 
DM (%) 4 10 0 0.096 0.043 
IGT and DM 
(%) 
39 55 20 0.029 0.004 
Migraine  
(%) 
14 13 13 0.836 0.836 
Thromboembolic 
disorder   
(%) 
6 1 2 0.054 0.149 
Inflammation  
(%) 
30 20 10 0.102 <0.001 
Psychiatric 
disorder  
(%) 
20 11 3 0.079 <0.001 
Triglyceride  
(mmol/L) 
1.0 ± 0.5 1.4 ± 0.7 1.0 ± 0.6 <0.001 0.096 
Cholesterol 
(mmol/L) 
5.1 ± 1.0 5.4 ± 1.1 5.6 ± 1.0 0.092 <0.001 
LDL-C  
(mmol/L) 
3.0 ± 0.8 3.5 ± 0,9 3.6 ± 0.8 0.002 <0.001 
HDL-C  
(mmol/L) 
1.6 ± 0.5 1.3 ± 0.4 1.6 ± 0.5 <0.001 1.000 
Values are mean ±SD. Significant p-values are indicated in bold fond. 
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Patients with MINCA had several established cardiovascular risk factors, 
mainly smoking, hypertension, impaired glucose tolerance (IGT) and diabetes 
mellitus (DM), inflammatory disease, and psychiatric disorders except for the 
lipid profile that was more favourable with low LDL and high HDL 
cholesterol (Table 3). These results are in line with a recent review of 
MINOCA patients except for the sex distribution, with more women in our 
study (72% vs 40%) 4. The differences may reflect our exclusion criteria such 
as myocarditis and patients < 35 years of age. Previous data regarding sex 
differences in myocarditis are limited and diverse but there is one study 
revealing a higher prevalence and increased myocardial involvement in 
younger men 123.  
A history of inflammatory disease was more common in patients with MINCA 
than in healthy controls, which is supported by the increase of C-reactive 
protein (CRP) at admission (Table 3). Hypercoagulability due to inflammation 
has been reported as a possible reason for MINCA. There are some case 
reports showing exacerbation of systemic inflammatory disease without 
evidence of vasculitis whereas others have identified secondary myocarditis 
due to vasospasm  124,125. One recent observational study found that older age, 
diabetes mellitus, hypertension, smoking and increased plasma levels of CRP 
in MINOCA were associated with new major adverse cardiovascular events 
similar to CHD 126.  
 
Table 4. Markers of atherosclerosis and myocardial dysfunction in patients with 
MINCA compared to CHD and healthy controls 
  MINCA CHD Control MINCA vs 
CHD 
MINCA  
vs Control 
Reactive hyperaemia (RHI) 
index 
2.2 ± 
0.7 % 
2.1 ± 
0.6 % 
2.3 ± 0.6 
% 
p = 0.141 p = 0.639 
Intima-media thickness (IMT) 
(mm) 
0.71 ± 
0.12 
0.74 ± 
0.16 
0.70 ± 
0.12 
p = 0.216 p = 0.855 
N-terminal pro brain 
natriuretic peptide  
(NT-pro-BNP)(ng/L) 
133 ± 
129 
274 ± 
460 
68 ± 74 p = 0.001 P < 0.001 
 Bold value indicates p ≤ 0.05. 
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NT-proBNP measured 3 months after the acute event was lower in patients 
with MINCA than in CHD controls but greater than in the healthy control, 
group indicating remaining myocardial stress (Table 4). One can speculate if 
these results could reflect our larger proportion of MINCA with TS under 
recovery, since elevated level of NT-proBNP is obligatory in TS 40. Other 
possible reasons could be other subgroups of MINCA with myocardial injury 
or coronary microvascular dysfunction 26,111  Unfortunately, we did not 
distinguish NT-pro-BNP between the different underlying causes for MINCA 
and NT-proBNP was not measured at admission for comparison. Also healthy 
women without cardiovascular disease are described with increased levels 
within the normal range of NT-pro-BNP 86. Since our study material consisted 
of mainly women (72%) the higher NT-proBNP values in MINCA compared 
to healthy controls are difficult to interpret further. 
Regardless of similar cardiovascular risk factors, with the exception of the 
lipid profile, as in patients with CHD, the measurements of atherosclerosis 
(RHI and IMT) were similar to healthy controls and did not differ significantly 
compared to CHD despite an adequate power calculation. Perhaps this could 
be explained by the CHD control group that in our study was younger and 
included mainly STEMI with single vessel disease that represents patients 
with less atherosclerosis 127. Also, since RHI was within the normal range for 
all groups one can discuss if certain medical therapies could have improved 
the endothelial function in our controls with CHD 128.  
Our conclusion is that despite many classical cardiovascular risk factors for 
CHD, patients with MINCA do not have signs of early atherosclerosis. Further 
studies with larger groups are needed to clarify a potential difference 
regarding atherosclerosis burden in MINCA including a comparison with a 
group with more severe CHD. 
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STUDY III: Effect of myocardial infarction with nonobstructive coronary 
arteries on physical capacity and quality-of-life 
 
The exercise stress test performed 6 weeks after admission in patients with 
MINCA showed lower work capacity compared to healthy controls (139 vs 
167 W) and higher work capacity compared to patients with CHD (124 W) 
(Figure 9).  
 
Figure 9. Work capacity in patients with MINCA and control groups 
 
 
The percentage maximal heart rate was lower in patients with MINCA and 
CHD than in the healthy controls. Further analysis comparing patients with 
MINCA and healthy controls without β-blockers therapy showed similar 
difference in work capacity between the groups (126 W vs 171W).   
Analysis of SF-36 performed 3 months after admission, showed that patients 
with MINCA had lower PCS and MCS scores compared to the healthy 
controls, including significantly lower values of all 8 domains. When 
comparing with CHD controls, we found lower vitality and mental health 
scores, whereas the rest of the dimensions were similar (Table 5).  
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Table 5. SF-36 dimensions and summary components in MINCA compared  
with control groups 
SF-36 dimensions and 
summary components 
MINCA 
n=90 
CHD 
control 
n=91 
Healthy 
control 
n=89 
MINCA vs   
CHD control  
     
      (p-value) 
MINCA vs  
healthy 
control  
(p-value) 
Physical function 83±21 82±19 94±11 0.500 <0.001 
Role physical 77±37 78±35 94±21 0.932 <0.001 
Body pain 68±29 74±28 83±22 0.157 <0.001 
General health 65±22 68±21 82±17 0.301 <0.001 
Vitality 55±23 64±25 73±20 0.008 <0.001 
Social function 79±24 83±23 93±16 0.192 <0.001 
Role emotional 71±41 76±39 94±22 0.384 <0.001 
Mental health 69±19 74±22 82±15 0.016 <0.001 
Physical Component 
summary (PCS) score 
49±9 49±9 53±7 0.980 <0.001 
Mental Component 
summary  (MCS) score 
43±12 47±12 51±8 0.012 <0.001 
Values are mean ±SD. Significant p-values are indicated in bold fond font.  
The MCS score was significantly lower in patients with MINCA compared to 
both control groups. This is supported by the rate of previous psychiatric 
disorders that was higher in MINCA (19%) compared to both the CHD (11%) 
and the healthy (3%) control groups. Our results might reflect our inclusion of 
a MINCA group that to a great extent consisted of patients with TS where 
emotional stress triggers are common 129. In fact, more than half of the patients 
with MINCA (59%) recalled physical and/or emotional distress before 
admission indicating the influence of psychological factors in their illness. 
There is one recent study that measured baseline SF-12 in patients with 
MINOCA younger than 55 years. The physical functioning as described by the 
PCS score was similar to our findings but the mental functioning scores 
(MCS) were better (48.6) in patients with MINOCA 59. The study did not use 
CMR imaging to exclude myocarditis which is reflected by the younger study 
group with less women (40%). Another explanation could be that our study 
consisted mainly of women in the menopausal status and that this condition is 
associated with higher rate of anxiety and depression symptoms 130. We also 
know that depression and reduced exercise capacity are risk factors for poor 
prognosis in patients with CHD but the relationship between the two is unclear 
131,132. Our conclusion is that patients with MINCA do have physical and 
mental distress 3 months after the acute event, similar or worse to patients 
with CHD. Recognition and treatment of decreased QoL, will probably 
improve both physical and mental health in the same way as for other cardiac 
diseases. 
  38 
STUDY IV:  Prevalence of anxiety and depression symptoms in patients with 
myocardial infarction with non-obstructive coronary arteries 
 
Patients with MINCA had higher scores on BDI compared with healthy 
controls and similar to CHD patients (Table 6). When using HADS-A, the 
score for anxiety was higher in MINCA compared with healthy controls and 
similar to CHD patients, and with HADS-D, the scores for depression were 
significantly higher in MINCA patients compared with healthy controls  and 
similar to CHD patients (Table 6 and Figure 10).  
 
Table 6. BDI and HADS scores in patients with MINCA compared with control groups                        
 
 
N=99 for MINCA and N=90 for CHD relating to BDI, N=98 for MINCA and N=89 for CHD relating to HADS. N=97 for 
healthy control relating to BDI and HADS. Values are presented as mean ± standard deviation or number (percent). 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINCA  
 
CHD 
 
Healthy 
 
MINCA vs 
CHD  
(p-value) 
MINCA vs 
Healthy  
(p-value) 
BDI 9.1±9.1 8.0±8.4 3.5±4.0 0.231 <0.001 
BDI >=10 35 (35) 27(30) 9(9) 0.954 0.006 
HADS 9.7±7.4 7.5±6.0 5.3±5.1 0.051 <0.001 
HADS-A 5.5±4.3 4.2±3.4 3.3±3.3 0.049 <0.001 
HADS-D 4.2±3.7 3.3±3.1 2.1±2.3  0.100 <0.001 
HADS-A >=8 26 (27) 19 (21) 9 (9) 0.409  0.002 
HADS-D >=8 17 (17) 12 (13) 4 (4) 0.467  0.003 
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Figure 10. Summary scores of the anxiety and depression subscales of HADS in patients 
with MINCA compared with control groups 
 
 
Boxes indicate 25th percentile, median, and 75th percentile. MINOCA = Myocardial infarction with non-obstructive  
coronary arteries, CHD = Coronary heart disease, HADS = Hospital Anxiety and Depression Scale. 
 
 
In our study, 25% had a definitive diagnosis of TS ,whereas another 19% had 
possible TS according to Mayo Clinic diagnostic criteria 47. Patients with 
MINCA and TS had an increased prevalence of depression as measured by the 
BDI, similar mean scores for depression (HADS-D) and a higher mean score 
for anxiety (HADS-A) than patients with MINCA without TS. BDI is more 
sensitive regarding depression and compared to HADS-D often results in 
higher scores, possibly due to the inclusion of somatic symptoms which may 
have contributed to the result 118. Our results are in line with a previous study 
that measured anxiety and depression, 3 months after the acute event in 
patients with TS with normal scores on the HADS-D (4.3) but increased 
scores on the HADS-A compared with controls with CHD 133.  
Patients with MINCA also had a high prevalence of previous psychiatric 
diagnoses especially when diagnosed with TS, and more than half of them 
reported emotional and/or physical distress within one week before admission. 
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One may speculate whether the anxiety and depression in patients with 
MINCA and especially TS is a consequence of psychiatric comorbidity. A 
sensitivity analysis which excluded patients with previous psychiatric 
diagnosis, speaks against this by showing similar results between the control 
groups, except for the anxiety subscale of HADS when compared with healthy 
controls.  
Furthermore, comparing HADS studies in patients with CHD, one study 
reported 38% with at least mild symptoms of anxiety (HADS-A >8) and 18% 
with mild symptoms of depression (HADS-D >8) during admission 134. There 
were improvements in mean scores for anxiety and depression between 
admission and the 3-month assessment, but no further changes were observed 
at one-year follow-up 134. Another study using HADS scores >8 in patients 
with a recent myocardial infarction, and the authors found 27% with anxiety 
and 13% with depression 6 weeks after the acute event where the results 
persisted at the 6-month follow-up 135. These findings suggest 6 weeks up to 3 
months as an optimal time to investigate for anxiety and depression.  
Studies show that risk factors for CHD, such as smoking, hyperlipidaemia, 
physical inactivity and hypertension, are more common in patients with 
anxiety and there are also indications that anxiety is an independent risk factor 
for negative cardiac outcomes across many different cardiac diseases 136. 
Depression in healthy persons without cardiac disease has been associated 
with future CHD and patients with anxiety during admission for a cardiac 
event are more likely to develop depression later on compared to patients 
without anxiety 137,138.  Since our studies reveal that patients with MINCA 
have similar cardiovascular risk factors and prevalence rates of anxiety and 
depression similar to patients with CHD, it may be assumed that these findings 
indicates a need for cardiac rehabilitation programmes in a comparable way to 
patients with CHD, to decrease the risk for cardiac events and to improve 
health and well-being. 
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GENERAL DISCUSSION 
 
In this thesis, which was based on the SMINC-study, we were able to find 
some of the different underlying causes of MINCA, describe risk markers and 
evaluate the QoL. The different use of the terms MINCA and MINOCA in 
these studies might appear confusing. Previously, and when our SMINC-study 
started, the term MINCA was used and has lately been changed to MINOCA 
in order to use the same definition as the angiographic guidelines and to stress 
the fact that this syndrome also can occur in the presence of non-obstructive 
coronary lesions <50% stenosis 9. Thus, in our studies patients with MINCA 
had a stricter definition of normal coronaries defined as <30% reduction of the 
coronary vessel wall and therefore our studies might have included more TS 
and myocarditis and excluded other diagnosis such as coronary spasm with or 
without plaque rupture/erosion. On the other hand we excluded patients with 
myocarditis in the screening phase and performed CT angiography in a subset 
of patients revealing that patients with MINCA and healthy controls were 
comparable regarding number of plaques139.  
The term MINOCA is not completely clear regarding underlying causes and 
prognosis and will most probably be revised for a better description and 
division of patients with ischemic-coronary and non-coronary disorders 140. 
Recently troponin-positive non-obstructive coronary arteries (TpNOCA) has 
been proposed as a description of patients with a suspected AMI in the 
absence of obstructive CHD and the term MINOCA or maybe ischemia and 
non-obstructive coronary arteries (INOCA) is then reserved only for those 
who have evidence of ischemia-related myocardial necrosis 141. 
 
CMR IMAGING IN MINCA  
 
In our first study approximately half of the patients with MINCA reached a 
definite final diagnosis, 26% with CMR and the rest by using Mayo diagnostic 
criteria for TS 47. Amongst patients considered to have normal findings on 
CMR-imaging, 33 (32%) were found to have typical signs of TS including 
reversible LV dysfunction. Of all patients screened with CMR imaging, 33 
(22%) were found to have TS. In addition, there were also cases of suspected 
milder forms of TS or TS under recovery. The estimated incidence of TS in 
MINOCA varies between 1%-22% 47,74,82,142. According to one CMR study in 
MINOCA, the time for CMR is crucial, especially in reversible conditions 
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such as myocarditis and TS 79. The authors concluded the importance of 
performing CMR imaging early, preferably within 2 weeks after the acute 
event, which provides the possibility of detecting myocardial damage before 
healing occurs, thereby increasing the amount of correct diagnosis. In the 
same study CMR  established a definitive diagnosis in 70% of patients with 
MINOCA and resulted in a change in the clinical management in 66 % of 
patients.   
Previous studies shows that patients with MINOCA could be burdened with 
the unclarity of their diagnosis and it has been reported that patients are more 
disturbed about the uncertainty of diagnosis and fear of prognosis than the 
chest pain experienced 6,143. Our findings highlight the importance of 
performing CMR in MINOCA, preferably with the latest T1 technique and at 
the right time for a better possibility of giving patients a correct diagnosis. 
With this approach we would be able to minimize the period of fear and 
uncertainty regarding the illness.  
 
RISK MARKERS IN MINCA 
The main result of the second study was that RHI and IMT were within the 
normal range in patients with MINCA indicating normal endothelial function. 
However, we were unable to demonstrate any differences compared to the 
CHD controls despite sufficient power of the study. Like in the review of 
Pasupathy et al patients with MINCA showed a similar cardiovascular risk 
factor profile as in patients with CHD, except for more favourable lipids 4. 
There are some studies proposing that RHI and IMT in a younger population 
better assess coronary atherosclerosis than classical risk factors and probably 
are better markers of CHD risk 144. Recent data showed that endothelial 
dysfunction was common in patients with TS, which can explain the theory of 
epicardial and/or microvascular coronary artery spasm in a similar way as in 
migraine or Raynaud´s phenomena 42,87,129. These findings are contradictory to 
our findings with mainly patients with TS, normal endothelial function and a 
prevalence of migraine in MINOCA that was similar to the control groups 
(Table 3).  
   43 
 
QUALITY-OF-LIFE, ANXIETY AND DEPRESSION IN MINCA  
The third study showed similar dimensions in SF-36 with lower mental and 
vitality scores in MINCA compared to patients with CHD. The physical 
domain of SF-36 which comprises physical function, role-physical, bodily 
pain, and general health showed that patients with MINCA had similar scores 
compared with CHD controls which correlated well with the measured lower 
physical capacity when compared with the healthy controls. Recently, QoL 
data on CHD patients measured by the shorter SF-12 together with HADS 
confirmed similar findings as in our CHD controls compared with healthy 
controls with decreased PCS and MCS 145. The authors concluded that the 
physical component of the SF-12 had a strong association with HADS and 
raised the question as to whether symptoms of anxiety and depression are an 
effect of the underlying physical condition. However, since patients with 
MINCA in our study did better on the exercise stress test than the CHD 
controls, their poor QoL cannot fully be explained by their exercise capacity. 
Our findings suggest that an acute overload of recent mental and/or physical 
stress with temporarily decreased myocardial function can explain the 
symptoms of fatigue and mental distress seen 3 months after the acute event. 
The fourth study, measuring anxiety and depression scores showed both high 
and similar rates to patients with CHD. Patients with MINCA and TS scored 
higher for anxiety and depression than those without. These findings of a high 
prevalence of anxiety and depression in MINCA measured by BDI and HADS 
are in line with our findings with low QoL scores in MINCA. One study 
supports an association between HADS-D and QoL since patients with 
depression after myocardial infarction were more likely than those without to 
have poor QoL 146. When comparing HADS subscales for anxiety and 
depression with SF-36 subscales, another study in patients with CHD found 
associations to all SF-36 subscales and most strongly to the mental health 
subscales indicating that the surveys measure similar aspects of mental health 
147.  
We know from previous studies that anxiety and depression in patients with 
CHD are associated with an increased risk of mortality and even more 
strongly if both conditions coexist 148,149. There are many theories about the 
link between anxiety and depression and CHD, such as disturbances in the 
autonomic nervous system and hypothalamic-pituitary-adrenal axis that can 
increase sympathetic nerve activity and catecholamine secretion, causing 
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inflammation and platelet activation 150. Depression is also associated with 
poor compliance with recommendations to reduce cardiovascular risk, such as 
quitting smoking, taking medications, exercising, and attending cardiac 
rehabilitation programs, which may lead to less optimal recovery and a worse 
prognosis 151. 
The predominance of post-menopausal women with TS suggests that 
decreased oestrogen is a possible factor for increased mental stress with 
sympathetic activation and catecholamine release triggering coronary 
microvascular dysfunction as a possible pathophysiological mechanism 41. 
From other studies, we have learned that middle-aged women have a high 
prevalence of both anxiety and depression, including panic attacks 150.  
Epidemiologic studies also show that women are up to 40% more likely to 
develop mental health disorders than men 152. The question remains whether 
the decline in mental health is a cause or consequence of MINOCA. 
 
STRENGTHS AND LIMITATIONS 
The strength of this study is the design with two types of age-and sex-matched 
controls and a detailed protocol that ensured strict exclusion of other 
conditions with similar symptoms, such as pulmonary embolism, myocarditis 
and other causes of type 2 myocardial infarction. On the other hand we used a 
stricter definition of what is considered MINOCA (<30% compared with 
<50% angiographic stenosis) and the results cannot, thus, be extrapolated to 
all patients with MINOCA.  
One limitation was that CMR imaging was performed in a median of 12 days 
after the acute event and that the CMR imaging technique only included T2 
sequences to detect oedema. The timing of CMR is of importance for the 
diagnosis of TS since the LV systolic dysfunction most often recovers within 
one week. The lack of intravascular imaging is also a limitation because it 
could have documented vulnerable plaques not visible on coronary 
angiography. However, CT angiography was performed in a subset of patients 
showing that patients with MINCA and healthy controls were comparable 
regarding plaque burden 139. Another limitation is that a large number of 
patients with MINOCA received β-blockers. Despite the analyses of exercise 
capacity in patients without β-blockers, we cannot exclude the possibility that 
β-blockers might have influenced the overall results, including QoL. We used 
two different validated questionnaires (the BDI and HADS) measuring anxiety 
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and depression. The BDI is more sensitive for depression and, compared with 
the HADS-D, often results in higher scores, possibly because of the inclusion 
of somatic symptoms which may have contributed to our results 118. The 
surveys cannot be used alone to diagnose anxiety and depression but are 
screening tools widely used for research purposes and only appropriate for use 
in case-control comparisons.   
 
FUTURE STUDIES 
The on-going SMINC-2 study in Stockholm Metropolitan Area where 
MINCA patients are investigated by CMR early after admission for MINCA 
(within 2-4 days) and with an updated CMR protocol and sensitive oedema 
sequences using T1 mapping 153. In addition, a non-invasive coronary 
tomography angiography (CTA) is performed one month after the acute event 
to detect plaques not visible on coronary angiography and to exclude coronary 
dissection. The aim is to find >70% of underlying diagnoses with CMR in 
MINCA and compare them with historical results from the SMINC-1 study. 
The study is also collecting data on QoL over time (from admission to 12 
months). All this will hopefully reduce the time of uncertainty and better 
describe recovery and well-being for our patients with MINCA.  
After the initial coronary angiography, including left ventriculography, and 
CMR, future studies in MINOCA should consider further investigations to 
detect ruptured plaques, coronary dissections, microvascular dysfunction and 
coronary spasm, according to the position paper 9. They suggested IVUS in 
connection with angiography and/or OCT as both can detect and characterize 
atherosclerotic plaques better than coronary angiography and coronary spasm 
provocation testing in cases of suspected coronary spasm. Laboratory test such 
as D-dimer to exclude pulmonary embolism, catecholamines to exclude 
pheochromocytoma, thrombophilia screening to exclude inherited causes of 
thromboembolism and NT-pro-BNP were also suggested.  
A recently started multinational study (MINOCA-BAT) that will randomize 
>5600 MINOCA patients to treatment with oral ACEI/ARBs and β-blockers 
versus matching no treatment will examine rates of death and other 
cardiovascular events after one year. Participating countries are Australia, 
Norway, Sweden, UK and USA.  
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CLINICAL IMPLICATIONS 
In connection with the CMR results from the screening-phase (Study I), our 
research group developed a protocol that has been used in Stockholm 
Metropolitan Area in order to use CMR routinely in patients with MINCA. 
After our main study we learned that patients with MINCA, despite similar 
cardiovascular risk factors as in patients with CHD, do not have any signs of 
early atherosclerosis measured by RHI and IMT. From this knowledge a basic 
treatment recommendation was given including aspirin and β-blockers, 
whereas other medications such as anti-platelet and lipid-lowering 
medications were excluded. This consensus was approved from expertise in 
this field. Meanwhile, we developed informative brochures about the MINCA 
syndrome, mainly for patients and their relatives. The third and fourth study 
confirmed our thoughts about reduced QoL and a high prevalence of anxiety 
and depression. In addition, during and after the SMINC study, patients with 
MINOCA were provided a yearly follow-up to increase our understanding and 
support for them. 
 
CONCLUSIONS 
CMR imaging is an important tool that can help us to identify the different 
underlying diagnoses in MINCA and enable a more appropriate treatment. 
Patients with MINCA do not have signs of early or generalized atherosclerosis 
and they share a number of cardiovascular risk factors with patients who have 
CHD, including high prevalence of anxiety and depression. There is also a 
decline in QoL similar to that of CHD patients and in some perspectives even 
worse in the domain of mental health. Altogether these findings show a high 
vulnerability to mental stress in patients with MINCA. The lack of clarity 
regarding diagnosis and treatment can also increase the stress and therefore 
highlight the need for a change in the management care of patients with 
MINCA, not only in the hospital but also after being discharged. Performing 
CMR early (2 weeks from presentation) and follow-up care in in a similar way 
as in patients with CHD will probably decrease the mental stress and improve 
QoL. 
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SVENSK SAMMANFATTNING 
Bakgrund: Hjärtinfarkt med normala kranskärl är ett vanligt tillstånd som främst drabbar medelålders 
kvinnor. Den bakomliggande orsaken är multifaktoriell och behöver utredas vidare för korrekt diagnos och 
behandling. Patienterna klagar ofta på brist av energi och verkar vara oroliga. Tidigare studier av MINCA 
(myocardial infarction with normal coronary arteries) patienter med kontrollgrupper saknades när Stockholm 
myocardial infarction and normal coronaries (SMINC) studien startade.  
Mål: Att beskriva resultaten från magnetisk resonanstomografi (MR) undersökning av hjärtat samt att 
beskriva bakgrunds karaktäristika, ateroskleros markörer och livskvalité (QOL) hos patienter med MINCA. 
Avsikten är att öka förståelsen och förbättra vården av denna grupp av patienter.   
Specifika mål, /metoder och resultat: 
Studie I: Syftet var att redovisa den verkliga förekomsten av myokardit och MINCA med eller utan 
hjärtinfarkt genom att använda MR undersökning av hjärtat. Resultaten visade att 67% av MINCA patienterna 
hade ett normalt fynd på MR hjärta, 19 % hade tecken på hjärtmuskelskada och 7% hade tecken på myokardit. 
Förekomsten av takotsubo syndrom (TS) i fallen med normal MR hjärta var 22 % vid användning av Mayo 
klinikens kriterium för TS. MR hjärta genomfördes i medeltal 12 dagar (6-28 dagar) efter insjuknandet. 
Studie 2: Syftet var att beskriva riskfaktorer genom att analysera CRF (clinical research form) samt 
undersökningar som genomfördes i samband med återbesöket 3 månader efter insjuknandet hos patienter med 
MINCA och jämföra dessa med kontrollgrupper. Undersökningar som genomfördes var blodprover, mätning 
av RHI (reactive hyperemia index) och IMT (intima-media thickness) genom att använda EndoPAT® (Itamar 
Medical Ltd) och ultraljud av halsartärer. Resultaten visade att patienter med MINCA har en likartad 
riskfaktorprofil som hos patienter med kranskärlssjukdom med undantag för en mer gynnsam lipidprofil. Den 
aterosklerotiska graden mätt som RHI och IMT var inom det normala intervallet hos patienterna med MINCA 
och likartade jämfört med båda friska och kranskärlssjuka kontroller. En bakomliggande psykiatrisk sjukdom 
var vanligare hos patienter med MINCA och TS än de utan TS och mer än hälften av alla MINCA patienter 
uppgav fysisk och emotionell stress i samband med insjuknandet. 
Studie 3: Syftet var att beskriva den fysiska arbetsförmågan och livskvaliteten från 6 veckor till 3 månader 
efter insjuknandet hos patienter med MINCA jämfört med kontroller genom att använda arbetstest på cykel 
och Short Form (SF)-36. Resultaten visade att patienter med MINCA hade en lägre fysisk arbetsförmåga och 
livskvalitet jämfört med friska kontroller. MINCA patienterna hade en något bättre arbetsförmåga jämfört 
med kranskärlssjuka kontroller men fick lägre poäng i den mentala komponenten av SF-36, i övrigt var 
dimensionerna likartade.  
Studie 4: Målet var att undersöka den psykiska hälsan hos patienter med MINCA och jämföra dem med 
kontrollgrupper genom att använda två olika frågeformulär 3 månader efter den akuta händelsen;              
Beck Depression Inventory (BDI) och Hospital Anxiety and Depression scale (HADS). Resultaten visade att 
ångest och depression är vanligt med en prevalens som liknar patienter med kranskärlssjukdom. Ångest är 
vanligare hos patienter med MINCA och TS än de utan TS.   
Slutsats: MR hjärta är ett viktigt instrument som kan hjälpa oss att identifiera de olika underliggande 
diagnoserna i MINCA syndromet vilket möjliggör en mer adekvat behandling. Patienter med MINCA har 
inga tecken på tidig eller generaliserad ateroskleros trots en likartad riskfaktorprofil som hos patienter med 
kranskärlssjukdom inklusive hög prevalens av ångest och depression. Det har även en likartad försämring av 
livskvaliten som hos patienter med kranskärlsjukdom och i några avseende även sämre i domänen för mental 
hälsa. Osäkerheten kring diagnos och behandling kan även öka stressen vilket betonar behovet av en 
förändring när det gäller omhändertagandet av MINCA patienterna, inte bara på sjukhuset men även efter 
utskrivningen. MR hjärta på ett tidigt stadium ( <2 veckor från insjuknandet) och en uppföljning på samma 
sätt som hos de kranskärlssjuka kommer troligtvis kunna minska den mentala stressen och förbättra 
livskvaliten.  
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